Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2010

01-12-2010 | Letter

A prophylactic vaccine for breast cancer? Why not?

Author: Vincent K Tuohy

Published in: Breast Cancer Research | Issue 6/2010

Login to get access

Excerpt

In a recent issue of Breast Cancer Research, Watson and Gusterson wrote a viewpoint article [1] about our strategy for developing a prophylactic breast cancer vaccine [2]. The authors base much of their view on several misconceptions and misrepresentations that we wish to clarify. …
Literature
1.
2.
Jaini R, Kesaraju P, Johnson JM, Altuntas CZ, Jane-Wit D, Tuohy VK: An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med. 2010, 16: 799-803. 10.1038/nm.2161.CrossRefPubMedPubMedCentral
3.
Robinson GW, McKnight RA, Smith GH, Hennighausen L: Mammary epithelial cells undergo secretory differentiation in cycling virgins but require pregnancy for the establishment of terminal differentiation. Development. 1995, 121: 2079-2090.PubMed
4.
Kleinberg DL, Todd J: α-Lactalbumin in human and subhuman primate normal mammary tissue and in human breast cancer as a marker for prolactin activity. Cancer Res. 1978, 38: 4318-4322.PubMed
5.
Walker RA: The demonstration of alpha lactalbumin in human breast carcinomas. J Pathol. 1979, 129: 37-42. 10.1002/path.1711290107.CrossRefPubMed
6.
Martin RH, Glass MR, Chapman C, Wilson GD, Woods KL: Suppression by bromocriptine of the serum lactalbumin peak associated with human lactogenesis. Clin Endocrinol (Oxf). 1981, 14: 363-366. 10.1111/j.1365-2265.1981.tb00621.x.CrossRef
7.
Clayton F, Sibley RK, Ordonez NG, Hanssen G: Argyrophilic breast carcinomas: evidence of lactational differentiation. Am J Surg Pathol. 1982, 6: 323-333. 10.1097/00000478-198206000-00005.CrossRefPubMed
8.
Lee AK, DeLellis RA, Rosen PP, Herbert-Stanton T, Tallberg K, Garcia C, Wolfe HJ: Alpha-lactalbumin as an immunohistochemical marker for metastatic breast carcinomas. Am J Surg Pathol. 1984, 8: 93-100. 10.1097/00000478-198402000-00002.CrossRefPubMed
9.
Lee AK, Rosen PP, DeLellis RA, Saigo PE, Gangi MD, Groshen S, Bagin R, Wolfe HJ: Tumor marker expression in breast carcinomas and relationship to prognosis. An immunohistochemical study. Am J Clin Pathol. 1985, 84: 687-696.CrossRefPubMed
10.
Cohen C, Sharkey FE, Shulman G, Uthman EO, Budgeon LR: Tumor associated antigens in breast carcinomas. Prognostic significance. Cancer. 1987, 60: 1294-1298. 10.1002/1097-0142(19870915)60:6<1294::AID-CNCR2820600622>3.0.CO;2-2.CrossRefPubMed
11.
Wrba F, Reiner A, Markis-Ritzinger E, Holzner JH, Reiner G, Spona J: Prognostic significance of immunohistochemical parameters in breast carcinomas. Pathol Res Pract. 1988, 183: 277-283.CrossRefPubMed
12.
Li X, Zhang J, Gao H, Vieth E, Bae KH, Zhang YP, Lee SJ, Raikwar S, Gardner TA, Hutchins GD, VanderPutten D, Kao C, Jeng MH: Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter. Mol Cancer Ther. 2005, 4: 1850-1859. 10.1158/1535-7163.MCT-05-0167.CrossRefPubMed
13.
Anderson LM, Swaminathan S, Zackon I, Tajuddin AK, Thimmapaya B, Weitzman SA: Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer. Gene Ther. 1999, 6: 854-864. 10.1038/sj.gt.3300909.CrossRefPubMed
14.
Anderson LM, Krotz S, Weitzman SA, Thimmapaya B: Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Ther. 2000, 7: 845-852. 10.1038/sj.cgt.7700191.CrossRefPubMed
15.
Thomas DL, Fraser NW: HSV-1 Therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Mol Ther. 2003, 8: 543-551. 10.1016/S1525-0016(03)00236-3.CrossRefPubMed
16.
Bailey AJ, Sloane JP, Trickey BS, Ormerod MG: An immunocytochemical study of α-lactalbumin in human breast tissue. J Pathol. 1982, 137: 13-23. 10.1002/path.1711370103.CrossRefPubMed
Metadata
Title
A prophylactic vaccine for breast cancer? Why not?
Author
Vincent K Tuohy
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2775

Other articles of this Issue 6/2010

Breast Cancer Research 6/2010 Go to the issue

Viewpoint

Prognostic gene network modules in breast cancer hold promise

Research article

Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk

Research article

A PALB2 mutation associated with high risk of breast cancer

Research article

Risk factors for ductal and lobular breast cancer: results from the nurses' health study

Review

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer

Research article

Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits